Inozyme Pharma (NASDAQ:INZY – Get Free Report) and Theratechnologies (NASDAQ:THTX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.
Earnings and Valuation
This table compares Inozyme Pharma and Theratechnologies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inozyme Pharma | N/A | N/A | -$71.17 million | ($1.56) | -1.79 |
| Theratechnologies | $81.76 million | 0.67 | -$23.96 million | ($0.10) | -12.00 |
Theratechnologies has higher revenue and earnings than Inozyme Pharma. Theratechnologies is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Analyst Recommendations
This is a summary of recent recommendations and price targets for Inozyme Pharma and Theratechnologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inozyme Pharma | 0 | 0 | 7 | 0 | 3.00 |
| Theratechnologies | 0 | 0 | 1 | 0 | 3.00 |
Inozyme Pharma presently has a consensus target price of $15.71, suggesting a potential upside of 463.24%. Given Inozyme Pharma’s higher possible upside, equities research analysts clearly believe Inozyme Pharma is more favorable than Theratechnologies.
Institutional & Insider Ownership
88.3% of Inozyme Pharma shares are owned by institutional investors. 11.2% of Inozyme Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Inozyme Pharma and Theratechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inozyme Pharma | N/A | -88.42% | -57.02% |
| Theratechnologies | -3.75% | N/A | -4.31% |
Summary
Inozyme Pharma beats Theratechnologies on 6 of the 11 factors compared between the two stocks.
About Inozyme Pharma
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
About Theratechnologies
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
